STUDY OBJECTIVE: To develop and evaluate a brief, easy-to-administer symptom assessment scale for use as a preference-based outcome measure in clinical trials and cost-effectiveness studies in asthma. DESIGN: Cross-sectional survey with 2-week reproducibility assessment. SETTING: Ambulatory care: university asthma and allergy center. PARTICIPANTS: One hundred sixty-one adults with asthma, 59% female, mean age 35+/-11 years. Mean FEV1 percent predicted was 86+/-17%. INTERVENTIONS: The 11-item Asthma Symptom Utility Index (ASUI). MEASUREMENTS AND RESULTS: Mean ASUI score for this sample was 0.71+/-0.23, with a range from 0.02 to 1.0. The ASUI was reproducible (intraclass correlation coefficient = 0.74) and able to distinguish patients known to differ on disease severity according to clinician ratings (p < 0.001) and by an asthma disease severity scale score (p < 0.001). The instrument was also significantly correlated with FEV1 percent predicted (r = 0.27, p < 0.001), the Asthma Quality of Life Questionnaire (r = 0.77, p < 0.001), and the Health Utilities Index Mark 2 (r = 0.36, p < 0.001). CONCLUSION: The results of this study support the reliability and validity of the ASUI, suggesting it will be a useful, complementary patient outcome measure for clinical trials and cost-effectiveness studies comparing treatment alternatives for persons with asthma.
STUDY OBJECTIVE: To develop and evaluate a brief, easy-to-administer symptom assessment scale for use as a preference-based outcome measure in clinical trials and cost-effectiveness studies in asthma. DESIGN: Cross-sectional survey with 2-week reproducibility assessment. SETTING: Ambulatory care: university asthma and allergy center. PARTICIPANTS: One hundred sixty-one adults with asthma, 59% female, mean age 35+/-11 years. Mean FEV1 percent predicted was 86+/-17%. INTERVENTIONS: The 11-item Asthma Symptom Utility Index (ASUI). MEASUREMENTS AND RESULTS: Mean ASUI score for this sample was 0.71+/-0.23, with a range from 0.02 to 1.0. The ASUI was reproducible (intraclass correlation coefficient = 0.74) and able to distinguish patients known to differ on disease severity according to clinician ratings (p < 0.001) and by an asthma disease severity scale score (p < 0.001). The instrument was also significantly correlated with FEV1 percent predicted (r = 0.27, p < 0.001), the Asthma Quality of Life Questionnaire (r = 0.77, p < 0.001), and the Health Utilities Index Mark 2 (r = 0.36, p < 0.001). CONCLUSION: The results of this study support the reliability and validity of the ASUI, suggesting it will be a useful, complementary patient outcome measure for clinical trials and cost-effectiveness studies comparing treatment alternatives for persons with asthma.
Authors: Janet T Holbrook; Robert A Wise; Benjamin D Gold; Kathryn Blake; Ellen D Brown; Mario Castro; Allen J Dozor; John J Lima; John G Mastronarde; Marianna M Sockrider; W Gerald Teague Journal: JAMA Date: 2012-01-25 Impact factor: 56.272
Authors: Janet T Holbrook; Elizabeth A Sugar; Robert H Brown; Lea T Drye; Charles G Irvin; Alan R Schwartz; Robert S Tepper; Robert A Wise; Razan Z Yasin; Michael F Busk Journal: Ann Am Thorac Soc Date: 2016-11
Authors: James B Johnson; Warren Summer; Roy G Cutler; Bronwen Martin; Dong-Hoon Hyun; Vishwa D Dixit; Michelle Pearson; Matthew Nassar; Richard Telljohann; Richard Tellejohan; Stuart Maudsley; Olga Carlson; Sujit John; Donald R Laub; Mark P Mattson Journal: Free Radic Biol Med Date: 2006-12-14 Impact factor: 7.376
Authors: Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker Journal: N Engl J Med Date: 2010-09-19 Impact factor: 91.245
Authors: John G Mastronarde; Nicholas R Anthonisen; Mario Castro; Janet T Holbrook; Frank T Leone; W Gerald Teague; Robert A Wise Journal: N Engl J Med Date: 2009-04-09 Impact factor: 91.245
Authors: Anne E Dixon; Emmanuelle M Clerisme-Beaty; Elizabeth A Sugar; Rubin I Cohen; Jason E Lang; Ellen D Brown; Joel E Richter; Charles G Irvin; John G Mastronarde Journal: J Asthma Date: 2011-08-08 Impact factor: 2.515
Authors: Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki Journal: Qual Life Res Date: 2011-08-04 Impact factor: 4.147
Authors: Sandra R Wilson; Robert A Wise; Mario Castro; Michael J Mulligan; Estela Ayala; Alan Chausow; Qiwen Huang; Santosh Gummidipundi Journal: J Allergy Clin Immunol Date: 2018-05-04 Impact factor: 10.793
Authors: Anne M Rentz; Jonathan W Kowalski; John G Walt; Ron D Hays; John E Brazier; Ren Yu; Paul Lee; Neil Bressler; Dennis A Revicki Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389